Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508765 | 0.88 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL14632327 | 0.84 | PTGDR2 (0.55) | PTGDR2 | |
| SCHEMBL508886 | 0.84 | PTGDR2 (0.54) | PTGDR2 | |
| SCHEMBL28384554 | 0.82 | PTGDR2 (0.44) | PTGDR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31395608 | 0.81 | PDE4A (0.53) | PTGDR2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL509094 | 0.80 | PTGDR2 (0.57) | PTGDR2 | |
| SCHEMBL14979169 | 0.78 | ALDH1A1 (0.59) | LMNAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31395703 | 0.78 | PTGDR2 (0.43) | PTGDR2LMNA | |
| SCHEMBL28807601 | 0.77 | BCL9 (0.51) | PTGDR2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL3322641 | 0.76 | RECQL (0.49) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668181-B1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8759386-B2 | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2668181-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| CN-103339125-A | Pyrazole compounds as CRTH2 antagonists | BOEHRINGER INGELHEIM INT | 2013-10-02 | — | — | CN | disclosed |
| US-20130023576-A1 | Pyrazole Compounds as CRTH2 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| WO-2012101043-A1 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023576-A1 | Pyrazole Compounds as CRTH2 Antagonists | HRH2, HRH1, HRH4 | PTGDR2 59/4885LMNA 3967/4885PDE4A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.